Medication info
Neurobalin Capsule 150 mg (Pregabalin)

Neurobalin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
White Life Science Co., Ltd.
Appearance
A hard capsule with a white or light yellow powder inside, with a white upper and lower part.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201901934 · Approved 2019.03.29 · Insurance code 625201860

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally, with or without food, as pregabalin in the total daily dose divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin: initial dose 150 (mg/day), maximum dose 600 (mg/day), administration BID or TID ≥30 -<60: initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under administration. b: The supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended. Adolescent patients 12 ~17 years of age: Use is not recommended.

Ingredients

Manufacturer
White Life Science Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It also helps in the adjunctive management of partial seizures in patients with epilepsy. Additionally, it is effective in alleviating symptoms of fibromyalgia. It contributes to improving the quality of life of patients suffering from various neurological disorders.

How to take

Adult dose

This medication is administered orally, with or without food, as pregabalin in the total daily dose divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin: initial dose 150 (mg/day), maximum dose 600 (mg/day), administration BID or TID ≥30 -<60: initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under administration. b: The supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended. Adolescent patients 12 ~17 years of age: Use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so if there are any changes in mood or behavior during treatment, consult a doctor immediately. Do not take this medication if you have an allergy to any of its components or specific genetic lactose intolerance. Diabetes patients should be cautious as they may gain weight after taking this medication, which might require adjustments to their blood sugar control medications. This medication can cause serious allergic reactions such as angioedema; if you experience facial or neck swelling or difficulty breathing, stop taking the medication immediately and seek medical attention. Elderly patients are at higher risk of falling or injury due to dizziness or drowsiness when taking this medication, so caution is advised. While taking this medication, blurred vision or changes in vision may occur, and these symptoms may improve upon discontinuation of the medication. Abrupt discontinuation of this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety, so the dosage should be gradually reduced according to a doctor's instructions. There is a risk of drug abuse, so patients with a history of drug abuse or mental health issues should use this medication with caution. Patients with decreased kidney function may need to adjust the dosage of this medication. Patients with severe heart disease should be cautious while taking this medication. Taking this medication with opioid analgesics may significantly enhance central nervous system depression, so consult healthcare professionals. In those with respiratory or neurological diseases, or in the elderly, there is an increased risk of severe respiratory depression, so caution is advised. Women of childbearing potential should use effective contraception when taking this medication in early pregnancy as it may be harmful to the fetus, and it is generally recommended not to take this medication during pregnancy. Caution is advised when driving or operating machinery due to the risk of accidents from dizziness and drowsiness. This medication can cause serious skin reactions, so if a rash or red spots appear, stop taking it and inform a doctor immediately. In the case of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur, so the prescribed dosage should be strictly adhered to, and treatment such as hemodialysis may be necessary if required. Keep this medication out of reach of children and do not transfer it to another container.

Side effects

  • suicidal impulse
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 211 more
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • respiratory failure
  • coma
  • death
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • direction impairment
  • irritability
  • depression
  • contentment
  • decreased libido
  • insomnia
  • depersonalization
  • hyperesthesia
  • restlessness
  • anxiety
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination impairment
  • balance disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysphonia
  • sensory abnormalities
  • sensory reduction
  • sedation
  • hypersomnia
  • cognitive impairment
  • nystagmus
  • speech impairment
  • myoclonic jerks
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremor with activity
  • fainting
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing impairment
  • blurred vision
  • diplopia
  • loss of indirect vision
  • visual impairment
  • visual field defect
  • photophobia
  • dry eyes
  • ocular swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • ocular irritation
  • mydriasis
  • during vibration
  • change in depth perception of vision
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • xerostomia
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme
  • delirium
  • paralysis
  • affective disorder
  • agitation
  • restlessness
  • worsening of seizures
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air or moisture. It is also recommended to store it at room temperature between 15 to 30 degrees Celsius, away from extreme heat or cold.

Appearance and packaging

Appearance

A hard capsule with a white or light yellow powder inside, with a white upper and lower part.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.